论文部分内容阅读
目的:探讨多西他赛抑制小鼠血管肉瘤细胞株ISOS 1增殖的作用,并与依托泊苷进行比较。方法:体外实验中采用AlamarBlue法检测多西他赛和依托泊苷对体外培养ISOS 1细胞的增殖抑制作用。体内实验中建立小鼠血管肉瘤模型 70只,各实验组与对照组均为 5只,均静脉或腹腔给药。静脉给药法每周 1次, 4次为一个疗程;腹腔给药法每日1次,连续 5次为一个疗程, 2wk后重复 1个疗程。多西他赛和依托泊苷均分为 5, 10, 20mg·kg-1不同剂量组,对照组给予等量生理盐水。观察肿瘤的体积和小鼠生存期。结果:体外实验中,多西他赛对ISOS 1的IC50为 15. 8μg·L-1,明显低于依托泊苷1. 175mg·L-1。体内实验中,静脉法给药时各剂量组,多西他赛比依托泊苷抗肿瘤效果好, 3个剂量组瘤体积抑制率均达 70%以上,多西他赛 5mg·kg-1组与依托泊苷 10mg·kg-1组延长生存期的作用相近。腹腔给药比静脉给药不良反应大, 20mg·kg-1的剂量几乎是致死剂量。结论:多西他赛对于小鼠血管肉瘤细胞株ISOS 1具有较强的增殖抑制作用且优于依托泊苷,低剂量每周 1次静脉给药,是安全有效的,为多西他赛临床应用于血管肉瘤的化疗提供了实验依据。
Objective: To investigate the effect of docetaxel on the proliferation of murine angiosarcoma cell line ISOS 1 and compare with etoposide. Methods: In vitro experiments using the AlamarBlue assay docetaxel and etoposide inhibition of proliferation of ISOS 1 cells in vitro. In vivo, 70 mice with angio-sarcoma models were established, and 5 in each experimental group and control group were given intravenous or intraperitoneal injection. Intravenous administration method 1 times a week, 4 times for a course of treatment; intraperitoneal administration method 1 day, 5 consecutive times for a course of treatment, 2wk repeat 1 course of treatment. Docetaxel and etoposide were divided into 5, 10, 20mg · kg-1 different doses of the control group was given the same amount of saline. Tumor volume and mouse survival were observed. Results: In vitro experiments, docetaxel for ICOS ICOS of 15.8μg · L-1, significantly lower than etoposide 1. 175mg · L-1. In vivo, the antitumor effect of docetaxel and etoposide was better in each dose group when administered intravenously, and the tumor volume inhibition rate reached more than 70% in 3 dose groups, and the dose of docetaxel 5 mg · kg -1 And etoposide 10mg · kg-1 group similar to the role of prolonging survival. Intraperitoneal administration than intravenous adverse reactions, 20mg · kg-1 dose is almost lethal dose. CONCLUSION: Docetaxel is a potent antiproliferative agent against mouse angiosarcoma cell line ISOS 1 and is more potent than etoposide. It is safe and effective to use low dose intravenous once a week for docetaxel The application of chemotherapy in angiosarcoma provides experimental evidence.